OA 200 mg daily as a single dose or in 2 divided doses. If necessary, 200 mg bd. RA 100-200 mg bd. Ankylosing spondylitis Initially 200 mg daily as a single dose or in 2 divided doses. If necessary, increase to 400 mg daily after 6 wk. Pain & dysmenorrhoea Initially 400 mg followed by an additional 200 mg, if necessary, on the 1st day; thereafter, 200 mg bd. Elderly Begin at lowest recommended dose. Moderate hepatic impairment Reduce dose by 50%.
View Favocox overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to celecoxib or to sulphonamides. Severe heart failure. Not for the treatment of peri-op pain in the setting of CABG surgery. Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 inhibitors. Severe CHF (NYHA III-IV). Severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh score ≥10). Estimated renal CrCl <30 mL/min. Women of childbearing potential unless using an effective method of contraception. Pregnancy & lactation. Childn <18 yr.
Patients in whom attacks of asthma, urticaria or acute rhinitis have been precipitated by aspirin or nonsteroidal anti-inflammatory agents. Patients w/ CV disease or risk factors for CV disease. GI risk. Not a substitute for acetylsalicylic acid for prophylaxis of CV thromboembolic diseases. Patients w/ history of cardiac failure or HTN. Reports of serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome & toxic epidermal necrolysis during post-marketing surveillance. Risk of renal effects. Closely monitor renal function. Elderly.
May diminish antihypertensive effect of ACE inhibitors. Reduced natriuretic effect of furosemide & thiazides. Increased rate of GI ulceration or other complications w/ aspirin. Increased plasma conc w/ fluconazole. Increased plasma conc of lithium. Caution when co-administered w/ warfarin, 2C9 inhibitors, drugs metabolized by CYP450 2D6.
Sign Out
